Aurobindo Pharma Ltd
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 15,690 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
Price Trend & Technical Volume
Daily QuotesPrice Chart (Historical Trend)
Interactive index-style Recharts with entry animations
4V Matrix
Multi-dimensional proprietary scoreValuation Comparison
Intrinsic & Fair Value Multiples* DCF valuation criteria: 2-Stage model: 10% growth rate years 1-5, 10.5% discount rate, 3% terminal growth rate
Community Sentiment
Be the first to voteWhat is your outlook on Aurobindo Pharma Ltd? Anonymous community voting — click an option to cast or update your vote.
AI Diagnostics Score
Weighted model combining fundamental, technical & growth factors.
- Debt/Equity is within safe range (0.20).
- Piotroski financial solvency score: 6/9.
- Momentum metrics indicate consolidation near key averages.
Historical Returns
Growth Analysis
| Metric | 1-Yr YoY | 3-Yr CAGR | 5-Yr CAGR |
|---|---|---|---|
| Sales | +6.1% | +10.6% | +6.3% |
| Profit | +0.6% | +22.0% | -8.1% |
Institutional Valuation Models & Fundamental Quality Methodology
DesiStocks synthesizes classical institutional valuation models and financial distress frameworks to provide a balanced, multi-dimensional view of Indian equity fundamentals. Review each methodology below to understand its core drivers, appropriate use cases, and inherent assumptions.
Projects operating cash flows minus capital expenditures over a 5-year forecast window, discounted back to present value using the Weighted Average Cost of Capital (WACC). Terminal value assumes a sustainable 4% perpetual growth rate matching India's long-term GDP expansion.
Rooted in classic value investing doctrine: √(22.5 × EPS × Book Value). Graham's formula sets a defensive price ceiling to ensure an investor never pays more than 15x earnings and 1.5x tangible book value simultaneously.
Anchored in Growth at a Reasonable Price (GARP). Equates a fair P/E multiple directly to the sustainable earnings growth rate percentage: Fair Price = EPS × Growth Rate. A PEG below 1.0 signifies potential undervaluation relative to growth.
Nine binary financial tests across profitability (positive ROA, cash flow > net income), balance sheet leverage (declining debt, rising liquidity, zero share dilution), and operational efficiency (improving gross margin and asset turnover). High scores (8–9) confirm robust quality.
Five weighted financial ratios assessing working capital, cumulative profitability, operating leverage, market capitalization, and asset turnover. Proven predictor of balance sheet stress and corporate bankruptcy probability over a 24-month horizon.
Proprietary four-pillar diagnostic framework examining Valuation (multiples vs 5Y history), Value Creation (ROCE spread over WACC cost of capital), Volatility (drawdown containment & beta), and Velocity (operating profit momentum).
All intrinsic valuations and scores are mathematical models generated using publicly available financial statements and historical market disclosures. These calculations do not represent guaranteed future price targets, investment advice, or research analyst buy/sell ratings under SEBI (Research Analysts) Regulations. Always perform independent diligence and consult a licensed financial advisor.